Core Viewpoint - Meikang Bio has obtained multiple medical device registration certificates for in vitro diagnostic reagents, enhancing its product line and market competitiveness [1] Group 1: Company Developments - Meikang Bio and its subsidiary Jiangxi Meikang have received several registration certificates issued by the Zhejiang and Jiangxi Provincial Drug Administration [1] - The registered products include Theophylline quality control products, Phenytoin quality control products, Angiotensin II and I testing kits, and Interleukin-1β, 2, and 2 receptor testing kits [1] - The acquisition of these certificates will enrich the company's product offerings in the field of in vitro diagnostic chemiluminescence and mass spectrometry [1] Group 2: Market Implications - The new certifications are expected to enhance the company's core competitiveness and market expansion capabilities [1] - However, the actual sales performance will depend on future marketing efforts, and the company is currently unable to predict the impact on future performance [1]